Low-dose 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine causes inflammatory activation of astrocytes in nuclear factor-κB reporter mice prior to loss of dopaminergic neurons

Journal of Neuroscience Research

Volumn 89, Issue 3, 2011, Pages 406-417

  Miller, James A ^a   Trout, Briana R ^a   Sullivan, Kelly A ^a   Bialecki, Russell A ^b   Roberts, Ruth A ^b   Tjalkens, Ronald B ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Astrocyte; MPTP; Neurodegeneration; Neuroinflammation; NF B

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ENHANCED GREEN FLUORESCENT PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CELL ACTIVATION; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG EFFECT; GAIT; LOCOMOTION; LOW DRUG DOSE; MALE; MOUSE; NERVOUS SYSTEM INFLAMMATION; NITRATION; NITROSATIVE STRESS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUBSTANTIA NIGRA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANALYSIS OF VARIANCE; ANIMALS; ASTROCYTES; CELL DEATH; COCULTURE TECHNIQUES; DISEASE MODELS, ANIMAL; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; GLIAL FIBRILLARY ACIDIC PROTEIN; GREEN FLUORESCENT PROTEINS; HINDLIMB; INFLAMMATION; MALE; MICE; MICE, TRANSGENIC; MOTOR ACTIVITY; NEURONS; NEUROTOXINS; NITRIC OXIDE SYNTHASE TYPE II; PROTEIN-SERINE-THREONINE KINASES; SUBSTANTIA NIGRA; TYROSINE; TYROSINE 3-MONOOXYGENASE;

EID: 78751687376     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.22549     Document Type: Article

References (53)

1. Allen JW, Mutkus LA, Aschner M. 2000. Current protocols in toxicology. New York: John Wiley & Sons. 12.4.1-12.4.15.
2. Amende I, Kale A, McCue S, Glazier S, Morgan JP, Hampton TG. 2005. Gait dynamics in mouse models of Parkinson's disease and Huntington's disease. J Neuroengineer Rehab 2: 20.
3. Aoki E, Yano R, Yokoyama H, Kato H, Araki T. 2009. Role of nuclear transcription factor kappa B (NF-kappaB) for MPTP(1-methyl-4-phenyl-1, 2, 3, 6-tetrahyropyridine)-induced apoptosis in nigral neurons of mice. Exp Mol Pathol 86: 57-64.
4. Ara J, Przedborski S, Naini AB, Jackson-Lewis V, Trifiletti RR, Horwitz J, Ischiropoulos H. 1998. Inactivation of tyrosine hydroxylase by nitration following exposure to peroxynitrite and 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP). Proc Natl Acad Sci U S A 95: 7659-7663.
5. Block ML, Hong JS. 2007. Chronic microglial activation and progressive dopaminergic neurotoxicity. Biochem Soc Trans 35: 1127-1132.
6. Brambilla R, Persaud T, Hu X, Karmally S, Shestopalov VI, Dvoriantchikova G, Ivanov D, Nathanson L, Barnum SR, Bethea JR. 2009. Transgenic inhibition of astroglial NF-kappa B improves functional outcome in experimental autoimmune encephalomyelitis by suppressing chronic central nervous system inflammation. J Immunol 182: 2628-2640.
7. Bywood PT, Johnson SM. 2000. Loss of tyrosine hydroxylase immunoreactivity in dendrites is a sensitive index of kainic acid-induced damage in rat substantia nigra neurons in vivo. Neurosci Lett 280: 5-8.
8. Camandola S, Mattson MP. 2007. NF-kappa B as a therapeutic target in neurodegenerative diseases. Expert Opin Ther Targets 11: 123-132.
9. Campbell A. 2004. Inflammation, neurodegenerative diseases, and environmental exposures. Ann N Y Acad Sci 1035: 117-132.
10. Carbone DL, Moreno JA, Tjalkens RB. 2008. Nuclear factor kappa-B mediates selective induction of neuronal nitric oxide synthase in astrocytes during low-level inflammatory stimulation with MPTP. Brain Res 1217: 1-9.
11. Carbone DL, Popichak KA, Moreno JA, Safe SH, Tjalkens RB. 2009. Suppression of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced nitric-oxide synthase 2 expression in astrocytes by a novel diindolylmethane analog protects striatal neurons against apoptosis. Mol Pharmacol 75: 35-43.
12. Champney TH, Hanneman WH, Nichols MA. 1992. Gamma-aminobutyric acid, catecholamine and indoleamine determinations from the same brain region by high-performance liquid chromatography with electrochemical detection. J Chromatogr 579: 334-339.
13. Chen H, Zhang SM, Hernán MA, Schwarzschild MA, Willett WC, Colditz GA, Speizer FE, Ascherio A. 2003. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol 60: 1059-1064.
14. Chia LG, Ni DR, Cheng FC, Ho YP, Kuo JS. 1999. Intrastriatal injection of 5, 7-dihydroxytryptamine decreased 5-HT levels in the striatum and suppressed locomotor activity in C57BL/6 mice. Neurochem Res 24: 719-722.
15. Cho I-H, Hong J, Suh EC, Kim JH, Lee H, Lee JE, Lee S, Kim C-H, Kim DW, Jo E-K, Lee KE, Karin M, Lee SJ. 2008. Role of microglial IKKbeta in kainic acid-induced hippocampal neuronal cell death. Brain 131: 3019-3033.
16. Collart MA, Baeuerle P, Vassalli P. 1990. Regulation of tumor necrosis factor alpha transcription in macrophages: involvement of four kappa B-like motifs and of constitutive and inducible forms of NF-kappa B. Mol Cell Biol 10: 1498-1506.
17. Fernagut PO, Diguet E, Labattu B, Tison F. 2002. A simple method to measure stride length as an index of nigrostriatal dysfunction in mice. J Neurosci Methods 113: 123-130.
18. Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurtig HI, Ischiropoulos H, Trojanowski JQ, Lee VM. 2000. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290: 985-989.
19. Hald A, Van Beek J, Lotharius J. 2007. Inflammation in Parkinson's disease: causative or epiphenomenal? Subcell Biochem 42: 249-279.
20. Hirsch EC, Hunot S. 2000. Nitric oxide, glial cells and neuronal degeneration in parkinsonism. Trends Pharmacol Sci 21: 163-165.
21. Hofele K, Sedelis M, Auburger GW, Morgan S, Huston JP, Schwarting RK. 2001. Evidence for a dissociation between MPTP toxicity and tyrosinase activity based on congenic mouse strain susceptibility. Exp Neurol 168: 116-122.
22. Jackson-Lewis V, Przedborski S. 2007. Protocol for the MPTP mouse model of Parkinson's disease. Nat Protoc 2: 141-151.
23. Jackson-Lewis V, Jakowec M, Burke RE, Przedborski S. 1995. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine. Neurodegeneration 4: 257-269.
24. Jobin C, Panja A, Hellerbrand C, Iimuro Y, Didonato J, Brenner DA, Sartor RB. 1998. Inhibition of proinflammatory molecule production by adenovirus-mediated expression of a nuclear factor kappaB super-repressor in human intestinal epithelial cells. J Immunol 160: 410-418.
25. Kalinin S, Richardson JC, Feinstein DL. 2009. A PPardelta agonist reduces amyloid burden and brain inflammation in a transgenic mouse model of Alzheimer's dsisease. Curr Alzheimer Res (in press).
26. Karin M, Ben-Neriah Y. 2000. Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu Rev Immunol 18: 621-663.
27. Kurkowska-Jastrzebska I, Wroñska A, Kohutnicka M, Czonkowska A. 1999. The inflammatory reaction following 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine intoxication in mouse. Exp Neurol 156: 50-61.
28. Liberatore GT, Jackson-Lewis V, Vukosavic S, Mandir AS, Vila M, McAuliffe WG, Dawson VL, Dawson TM, Przedborski S. 1999. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med 5: 1403-1409.
29. Liu X, Buffington JA, Tjalkens RB. 2005. NF-kappaB-dependent production of nitric oxide by astrocytes mediates apoptosis in differentiated PC12 neurons following exposure to manganese and cytokines. Brain Res Mol Brain Res 141: 39-47.
30. Lucas S-M, Rothwell NJ, Gibson RM. 2006. The role of inflammation in CNS injury and disease. Br J Pharmacol 147( Suppl 1): S232-S240.
31. Magness ST, Jijon H, Van Houten Fisher N, Sharpless NE, Brenner DA, Jobin C. 2004. In vivo pattern of lipopolysaccharide and anti-CD3-induced NF-kappa B activation using a novel gene-targeted enhanced GFP reporter gene mouse. J Immunol 173: 1561-1570.
32. McGeer PL, McGeer EG. 2008. Glial reactions in Parkinson's disease. Mov Disord 23: 474-483.
33. McGeer PL, Itagaki S, Boyes BE, McGeer EG. 1988. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38: 1285-1291.
34. Mena MA, García de Yébenes J. 2008. Glial cells as players in parkinsonism: the "good, " the "bad, " and the "mysterious" glia. Neuroscientist 14: 544-560.
35. Mitsumoto Y, Watanabe A, Mori A, Koga N. 1998. Spontaneous regeneration of nigrostriatal dopaminergic neurons in MPTP-treated C57BL/6 mice. Biochem Biophys Res Commun 248: 660-663.
36. Nagatsu T, Mogi M, Ichinose H, Togari A. 2000. Cytokines in Parkinson's disease. J Neural Transm Suppl, p 143-151.
37. Nakano H, Shindo M, Sakon S, Nishinaka S, Mihara M, Yagita H, Okumura K. 1998. Differential regulation of IkappaB kinase alpha and beta by two upstream kinases, NF-kappaB-inducing kinase and mitogen-activated protein kinase/ERK kinase kinase-1. Proc Natl Acad Sci U S A 95: 3537-3542.
38. Perkins ND. 2000. The Rel/NF-kappa B family: friend and foe. Trends Biochem Sci 25: 434-440.
39. Redfern W, Ewart L, Hammond T, Bialecki R, Kinter L, Lindgren S, Pollard C, Roberts R, Rolf MG, Valentin JP. 2010. Impact and frequency of different toxicities throughout the pharmaceutical drug development process. Toxicologist 14: 1081.
40. Rojo LE, Fernández JA, Maccioni AA, Jimenez JM, Maccioni RB. 2008. Neuroinflammation: implications for the pathogenesis and molecular diagnosis of Alzheimer's disease. Arch Med Res 39: 1-16.
41. Saijo K, Winner B, Carson CT, Collier JG, Boyer L, Rosenfeld MG, Gage FH, Glass CK. 2009. A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death. Cell 137: 47-59.
42. Sedelis M, Hofele K, Auburger GW, Morgan S, Huston JP, Schwarting RK. 2000. MPTP susceptibility in the mouse: behavioral, neurochemical, and histological analysis of gender and strain differences. Behav Genet 30: 171-182.
43. Sedelis M, Schwarting RK, Huston JP. 2001. Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behav Brain Res 125: 109-125.
44. Sriram K, Matheson JM, Benkovic SA, Miller DB, Luster MI, O'Callaghan JP. 2002. Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease. FASEB J 16: 1474-1476.
45. Szekely CA, Zandi PP. 2010. Non-steroidal anti-inflammatory drugs and Alzheimer's disease: the epidemiological evidence. CNS Neurol Disord Drug Targets 9: 132-139.
46. Tillerson JL, Caudle WM, Reverón ME, Miller GW. 2002. Detection of behavioral impairments correlated to neurochemical deficits in mice treated with moderate doses of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine. Exp Neurol 178: 80-90.
47. Tjalkens RB, Liu X, Mohl B, Wright T, Moreno JA, Carbone DL, Safe SH. 2008. The peroxisome proliferator-activated receptor-gamma agonist 1, 1-bis(3'-indolyl)-1-(p-trifluoromethylphenyl) methane suppresses manganese-induced production of nitric oxide in astrocytes and inhibits apoptosis in cocultured PC12 cells. J Neurosci Res 86: 618-629.
48. Vermeulen L, De Wilde G, Notebaert S, Vanden Berghe W, Haegeman G. 2002. Regulation of the transcriptional activity of the nuclear factor-kappaB p65 subunit. Biochem Pharmacol 64: 963-970.
49. Wang T, Zhang X, Li JJ. 2002. The role of NF-kappaB in the regulation of cell stress responses. Int Immunopharmacol 2: 1509-1520.
50. West MJ, Gundersen HJ. 1990. Unbiased stereological estimation of the number of neurons in the human hippocampus. J Comp Neurol 296: 1-22.
51. Whitton PS. 2007. Inflammation as a causative factor in the aetiology of Parkinson's disease. Br J Pharmacol 150: 963-976.
52. Wilms H, Zecca L, Rosenstiel P, Sievers J, Deuschl G, Lucius R. 2007. Inflammation in Parkinson's diseases and other neurodegenerative diseases: cause and therapeutic implications. Curr Pharm Des 13: 1925-1928.
53. Xie QW, Kashiwabara Y, Nathan C. 1994. Role of transcription factor NF-kappa B/Rel in induction of nitric oxide synthase. J Biol Chem 269: 4705-4708.